纳米晶药物的应用及展望  

Application and Prospects of Nanocrystalline Drugs

作　　者：王若楠 袁鹏辉 杨德智[1] 张丽[1] 吕扬[1] WANG Ruonan;YUAN Penghui;YANG Dezhi;ZHANG Li;LYU Yang(Beijing Key Laboratory of Polymorphic Drugs,Institute of Materia Medica,Chinese Academy of Medical Sciences,Beijing 100050,China)

机构地区：[1]北京协和医学院、中国医学科学院药物研究所、晶型药物研究北京市重点实验室,北京100050

出　　处：《医药导报》2020年第8期1100-1106,共7页Herald of Medicine

基　　金：国家重点研发计划(2016YFC1000900);国家科技重大专项一重大新药创制(2017ZX09101001,2018ZX09711001-010);中国医学科学院医学与健康科技创新工程(2017-12M-1-010);国家自然科学基金资助项目(81703473)。

摘　　要：纳米晶药物将纳米技术和晶型研究有机结合,有望提高药物的溶解度,改善成药性,减少副反应,其稳定性的控制和纳米晶药物-聚合物的组合在缓控释制剂、靶向给药领域的研究具有极大的应用价值。该文通过查阅国内外文献,论述了纳米晶药物的相关概念、制备方法及影响因素、纳米晶药物的当前研究进展及对未来研究的展望。Nanocrystalline drugs,based on the combination of nanotechnology and crystal technology,are expected to improve the solubility and the druggability,and reduce side reactions.The stability control and the combination of nanocrystalline drugs and polymers have great application values in the field of sustained and controlled release preparations and targeted drug delivery.This paper introduces the related concepts,preparation methods,influencing factors of nanocrystalline drugs,and discusses the current research progress and the prospects by consulting relative domestic and foreign literatures.

关 键 词：纳米晶药物 晶型技术 制备技术 分析技术 缓控释制剂 

分 类 号：R91[医药卫生—药学]